department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ondansetron · pharmadog

pharmadog
drugs
Ondansetron

drug

patient view →

ondansetron ODT

Marketedupdated 2mo ago

by Ipca Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(24)

approval · 23

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

ONDANSETRON — FDA approval

ondansetron ODT

phase 2 initiation · 1

phase 2 initiation

Chongqing Cancer Hospital — ondansetron (Phase II Trial Initiation)

ondansetron ODT

view all 24 catalysts →

News(0)

no news has mentioned this drug yet

brand

Ondansetron

generic

ondansetron

indication

Post Operative Nausea And Vomiting

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 23, 2029

~3.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jul 13, 2030formulationUS 90955774.0y
Jul 13, 2030formulationUS 90955774.0y
Nov 23, 2029formulationUS 85808303.4y
Nov 23, 2029formulationUS 85808303.4y

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval382 co-mentions · 163 sources
drugONDANSETRON250 co-mentions · 166 sources
drugondansetron hydrochloride ODT250 co-mentions · 166 sources
drugondansetron hydrochloride CR208 co-mentions · 124 sources
drugONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE208 co-mentions · 124 sources
drugONDANSETRON HYDROCHLORIDE208 co-mentions · 124 sources
tagSmall Molecule92 co-mentions · 92 sources
companyAurobindo Pharma Ltd29 co-mentions · 29 sources

Trials studying ondansetron ODT

phase2Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)recruitingn=95
—Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
phase1Phase I PK and Safety Study of Ondansetron Inhalation Powdercompletedn=24
phase3A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HECcompletedn=942
phase1A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesitycompletedn=59
phase4Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)completedn=414
phase1Buprenorphine-Fentanyl Interaction Studycompletedn=22
phase2A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adultscompletedn=235

more trials →